Evidence map›Paper›PMID 34162370›Full record

ArticleJournal of nanobiotechnology2021

Fe-doped chrysotile nanotubes containing siRNAs to silence SPAG5 to treat bladder cancer.

Jianye Liu, Yi Zhang, Hongliang Zeng, Long Wang, Qun Zhang, Pei Wu, Xiaoming Liu, Hongyi Xie, Wei Xiang, Biao Liu and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Jianye Liu *Department of Urology, The Third Xiangya Hospital of Central South University, Changsha, 410013, China.
Yi Zhang *School of Minerals Processing and Bioengineering, Central South University, Changsha, 410083, China.
Hongliang ZengResearch Institute of Chinese Medicine, Hunan Academy of Chinese Medicine, Changsha, 410013, China.
Long WangDepartment of Urology, The Third Xiangya Hospital of Central South University, Changsha, 410013, China.
Qun ZhangDepartment of Radiotherapy, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, China.
Pei WuDepartment of Operation Center, The Second Xiangya Hospital of Central South University, Changsha, 410008, China.
Xiaoming LiuDepartment of Digestive, The Third Xiangya Hospital of Central South University, Changsha, 410013, China.
Hongyi XieSchool of Minerals Processing and Bioengineering, Central South University, Changsha, 410083, China.
Wei XiangDepartment of Urology, The Third Xiangya Hospital of Central South University, Changsha, 410013, China.
Biao LiuDepartment of Urology, The Third Xiangya Hospital of Central South University, Changsha, 410013, China.
Jiahao LiuDepartment of Urology, The Third Xiangya Hospital of Central South University, Changsha, 410013, China.
Xuewen LiuDepartment of Oncology, The Third Xiangya Hospital of Central South University, No.138, Tongzipo Road, Changsha, 410013, Hunan, China.
Jianfei XieDepartment of Nursing, The Third Xiangya Hospital of Central South University, Changsha, 410013, China.
Jin TangDepartment of Urology, The Third Xiangya Hospital of Central South University, Changsha, 410013, China.
Zhi LongDepartment of Urology, The Third Xiangya Hospital of Central South University, Changsha, 410013, China.
Leye HeDepartment of Urology, The Third Xiangya Hospital of Central South University, Changsha, 410013, China.
Mengqing XiaoDepartment of Oncology, The Third Xiangya Hospital of Central South University, No.138, Tongzipo Road, Changsha, 410013, Hunan, China.
Liang XiangDepartment of Oncology, The Third Xiangya Hospital of Central South University, No.138, Tongzipo Road, Changsha, 410013, Hunan, China.
Ke CaoDepartment of Oncology, The Third Xiangya Hospital of Central South University, No.138, Tongzipo Road, Changsha, 410013, Hunan, China. csucaoke@163.com.

Funding

Huxiang Young Talents Plan Project of Hunan Province 2019RS2015National Natural Science Foundation of China 81802556Natural Science Foundation of Hunan Province 2019JJ30039New Xiangya Talent Projects of the Third Xiangya Hospital of Central South University JY201615Scientific Projects of Changsha Administration of Science &Technology kq1901129Scientific Projects of Health Commission of Hunan Province 20201041Scientific Projects of Health Commission of Hunan Province B2017034
6 · The paper itself

Abstract

backgroundFor certain human cancers, sperm associated antigen 5 (SPAG5) exerts important functions for their development and progression. However, whether RNA interference (RNAi) targeting SPAG5 has antitumor effects has not been determined clinically.

resultsThe results indicated that Fe-doped chrysotile nanotubes (FeSiNTs) with a relatively uniform outer diameter (15-25 nm) and inner diameter (7-8 nm), and a length of several hundred nanometers, which delivered an siRNA against the SPAG5 oncogene (siSPAG5) efficiently. The nanomaterials were designed to prolong the half-life of siSPAG5 in blood, increase tumor cell-specific uptake, and maximize the efficiency of SPAG5 silencing. In vitro, FeSiNTs carrying siSPAG5 inhibited the growth, migration, and invasion of bladder cancer cells. In vivo, the FeSiNTs inhibited growth and metastasis in three models of bladder tumors (a tail vein injection lung metastatic model, an in-situ bladder cancer model, and a subcutaneous model) with no obvious toxicities. Mechanistically, we showed that FeSiNTs/siSPAG5 repressed PI3K/AKT/mTOR signaling, which suppressed the growth and progression of tumor cells.

conclusionsThe results highlight that FeSiNTs/siSPAG5 caused no activation of the innate immune response nor any systemic toxicity, indicating the possible therapeutic utility of FeSiNTs/siSPAG5 to deliver siSPAG5 to treat bladder cancer.

Indexed as

AnimalsAsbestos, SerpentineCell Cycle ProteinsCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticGene Knockdown TechniquesGene SilencingGenetic TherapyHumansMaleMiceMice, Inbred BALB CMice, NudeNanotubesAsbestos, SerpentineCell Cycle ProteinsMTOR protein, humanPhosphatidylinositol 3-KinasesRNA, Small InterferingSPAG5 protein, humanTOR Serine-Threonine KinasesBladder cancerFe-doped chrysotile nanotubesGene therapySiRNA-SPAG5Targeted delivery

Identifiers

PMID34162370
PMCPMC8220725

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.